SCHEMBL19289959

SCHEMBL19289959

CC(I)NC(Cc1ccccc1)C(=O)Nc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.52
▸ KMT2A Q03164 3/20 0.52
▸ NPC1 O15118 1/20 0.52
▸ RAB9A P51151 1/20 0.52
▸ MAPT P10636 3/20 0.50
▸ CYP2D6 P10635 2/20 0.50
▸ IDO1 P14902 1/20 0.49
▸ GPR142 Q7Z601 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ FPR2 P25090 3/20 0.47
▸ KDM1A O60341 3/20 0.46
▸ MAOA P21397 2/20 0.46
▸ KDM1B Q8NB78 1/20 0.46
▸ RCOR1 Q9UKL0 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16252298 0.88 MEN1 (0.55) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL19289957 0.84 LMNA (0.55) MEN1KMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL23156997 0.83 MME (0.55) NPC1RAB9AFPR2
SCHEMBL19289818 0.82 MME (0.49) NPC1RAB9ACYP3A4
SCHEMBL16254380 0.81 CYP2D6 (0.54) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL13478005 0.81 MEN1 (0.55) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL16252305 0.79 POLB (0.59) MEN1KMT2ANPC1RAB9ACYP2D6
SCHEMBL18435147 0.79 GPR142 (0.57) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL2845806 0.78 MEN1 (0.79) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL24833252 0.76 EPHX1 (0.53) MEN1KMT2ANPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2861581-B9 1,2,3,4-Tetrahydroisoquinoline-pyrrolidine derivatives as antagonists of apoptosis (IAPs) for the treatment of cancer. BRISTOL MYERS SQUIBB CO (US) 2017-08-30 — — EP disclosed
Send feedback